Leukemia Drugs Market Research Reports

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report

  • Report
  • 156 Pages
From
MarketVIEW: CAR-T Cell Therapy For Multiple Myeloma Disease and Pipeline Summary - Product Thumbnail Image

MarketVIEW: CAR-T Cell Therapy For Multiple Myeloma Disease and Pipeline Summary

  • Report
  • 110 Pages
Market Spotlight: Myelodysplastic Syndrome (MDS) - Product Thumbnail Image

Market Spotlight: Myelodysplastic Syndrome (MDS)

  • Report
  • 45 Pages
From
Market Spotlight: Myelofibrosis - Product Thumbnail Image

Market Spotlight: Myelofibrosis

  • Report
  • 30 Pages
From
Drug analysis: Sprycel - Product Thumbnail Image

Drug analysis: Sprycel

  • Drug Pipelines
  • 23 Pages
From
Drug analysis: asciminib - Product Thumbnail Image

Drug analysis: asciminib

  • Drug Pipelines
  • 12 Pages
From
Drug analysis: Gleevec - Product Thumbnail Image

Drug analysis: Gleevec

  • Drug Pipelines
  • 29 Pages
From
Drug analysis: Bosulif - Product Thumbnail Image

Drug analysis: Bosulif

  • Drug Pipelines
  • 14 Pages
From
Drug analysis: Iclusig - Product Thumbnail Image

Drug analysis: Iclusig

  • Drug Pipelines
  • 25 Pages
From
Drug analysis: Tasigna - Product Thumbnail Image

Drug analysis: Tasigna

  • Drug Pipelines
  • 17 Pages
From
Drugs Analysis: Synribo - Product Thumbnail Image

Drugs Analysis: Synribo

  • Report
  • 12 Pages
From
Drug Analysis: Ofatumumab - Product Thumbnail Image

Drug Analysis: Ofatumumab

  • Drug Pipelines
  • 10 Pages
From
Global Leukemia Cancer Market Research and Forecast 2018-2023 - Product Thumbnail Image

Global Leukemia Cancer Market Research and Forecast 2018-2023

  • Report
From
Global Leukemia Partnering 2012 to 2018 - Product Thumbnail Image

Global Leukemia Partnering 2012 to 2018

  • Report
  • 150 Pages
From
Global Acute and Chronic Myelogenous Leukemia Partnering 2012 to 2018 - Product Thumbnail Image

Global Acute and Chronic Myelogenous Leukemia Partnering 2012 to 2018

  • Report
  • 150 Pages
From
Leukaemia Forecast in 18 Major Markets 2017-2027 - Product Thumbnail Image

Leukaemia Forecast in 18 Major Markets 2017-2027

  • Report
  • 82 Pages
From
BCMA Targeted Therapies, 2017-2030 - Product Thumbnail Image

BCMA Targeted Therapies, 2017-2030

  • Report
  • 143 Pages
From
Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments - Product Thumbnail Image

Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments

  • Report
  • 119 Pages
From
Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments - Product Thumbnail Image

Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments

  • Report
  • 117 Pages
From
Primary Myelofibrosis Forecast in 8 Major Markets 2016-2026 - Product Thumbnail Image

Primary Myelofibrosis Forecast in 8 Major Markets 2016-2026

  • Report
  • 40 Pages
From
Loading Indicator

On average over 40,000 are diagnosed with leukemia each year in the United States. It is also one of the most common cancers in children. Large differences in therapeutic outcomes exist among patient groups such as children and old age sufferers, and according to the form of a disease that has many variants such as Acute (AML) and Chronic (CML) Myelocytic Leukemia, Acute (ALL) and Chronic (CLL) Lymphocytic Leukemia, and Hairy Cell Leukemia (HCL). These variations have led to unmet needs among specific patient groups. The selection of expert and insightful reports in this section enable you explore these market opportunities by providing key industry data such as drug development strategies, international market trends and forecasts and profiles of major players like Novartis, Pfizer and Bristol-Myers Squibb. Show Less Read more

adroll